• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    11/14/24 3:09:02 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email
    SC 13G/A 1 cormorant-crbp093024a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Corbus Pharmaceuticals Holdings, Inc.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    21833P301

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  21833P301
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Cormorant Asset Management, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,375,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,375,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,375,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    19.50%
    12
    TYPE OF REPORTING PERSON
     
    IA

     
     


     

    CUSIP No.  21833P301
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Bihua Chen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) x
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,375,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,375,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,375,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    19.50%
    12
    TYPE OF REPORTING PERSON
     
    IN
     
     


     

     

    CUSIP No. 21833P301
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Corbus Pharmaceuticals Holdings, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    500 River Ridge Drive

    Norwood, MA 02062

    Item 2.(a) Names of Person Filing:

    Cormorant Asset Management, LP

    Bihua Chen

    This statement is filed by (i) Cormorant Asset Management, LP ("Cormorant"), a Delaware limited partnership, and the investment adviser to certain funds (the "Cormorant Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the Cormorant Funds and (ii) Bihua Chen ("Ms. Chen") with respect to the Shares directly held by the Cormorant Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 2.(b) Address of Principal Business Office:

    200 Clarendon Street, 52nd Floor

    Boston, MA 02116

     

    Item 2.(c) Citizenship:

    Cormorant Asset Management, LP - Delaware

    Bihua Chen - United States

     

    Item 2.(d) Title of Class of Securities

    Common Stock (the "Shares")

     

    Item 2.(e) CUSIP No.:

    21833P301

     

    CUSIP No.  21833P301
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 21833P301
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the Securities and Exchange Commission on November 7, 2024, that there were 12,179,482 shares of voting Common Stock of the Issuer outstanding as of November 4, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    See Item 2. The Cormorant Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a -11.

     

     
    CUSIP No. 21833P301
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           

     

     
    CUSIP No. 21833P301
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Cormorant Asset Management, LP

    By: Cormorant Asset Management GP, LLC

    its General Partner

           
      By:  /s/ Bihua Chen
        Bihua Chen, Managing Member
           
     

    Bihua Chen

           
      By:  /s/ Bihua Chen
        Bihua Chen
           
    Get the next $CRBP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    3/6/2024$4.00 → $46.00Hold → Buy
    Jefferies
    More analyst ratings

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/11/24 5:34:06 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/6/24 4:00:46 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Corbus Pharma

      William Blair initiated coverage of Corbus Pharma with a rating of Outperform

      2/28/25 7:22:12 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corbus Pharma

      Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

      12/2/24 9:55:40 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Corbus Pharma with a new price target

      Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00

      7/30/24 6:19:42 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

      No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety and pharmacokinetics (PK) data analysis of the single ascending dose (SAD) study launched in March. The MAD portion of this clinical study is scheduled for completion in the third quarter of this

      6/30/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

      Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule for later this year   NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3

      6/25/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

      NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire side chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. Piper Sandler clients can register for the event through their representative. Corbus Fireside ChatJune 26, 2025, 10:00 a.m. ETHosted by Biren Amin, Managing DirectorPipe Sandler - Healthcare Equity Research About CorbusCorbus Pharmaceut

      6/24/25 4:05:00 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    SEC Filings

    See more
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/19/25 8:30:10 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

      10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 4:21:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 8:30:09 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Altmeyer Anne sold $10,096 worth of shares (1,392 units at $7.25) and was granted 4,800 shares, increasing direct ownership by 122% to 6,191 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      6/2/25 4:30:13 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jenkins John Kenneth sold $20,465 worth of shares (2,783 units at $7.35) and was granted 4,800 shares, increasing direct ownership by 72% to 4,833 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      6/2/25 4:30:16 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kung Winston was granted 4,800 shares, increasing direct ownership by 86% to 10,366 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      6/2/25 4:30:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 7:48:14 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 6:41:20 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:05:29 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

      NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

      5/19/25 8:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

      NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

      8/20/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

      NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

      2/28/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care